Lion Point Capital, LP
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Lion Point Capital, LP reported 35 stock positions worth $20.9 million. Its top holding was Cue Biopharma (CUE) at 8.0% of the portfolio, followed by Praxis Precision Medicines I (PRAX, 7.1%) and Moonlake Immunotherapeutics (MLTX, 6.3%). Compared with Q1 2026, it opened 1 new position and sold out of 1. The biggest buy was a new position in Cue Biopharma (CUE) and the biggest sale an exit from Cue Biopharma (CUE).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001643354
- Portfolio Value
- $20.9M (Q2 2026)
- SEC Filing
- 0001013594-26-000908 ↗ filed Aug 14, 2026
Holdings Value
Holdings 35 stocks · $20.9M
| CUE Cue Biopharma Inc. | 7.99% | 52,928 | $1.7M | New |
| PRAX Praxis Precision Medicines I | 7.13% | 4,450 | $1.5M | No change |
| MLTX Moonlake Immunotherapeutics | 6.29% | 67,500 | $1.3M | No change |
| FENC Fennec Pharmaceuticals Inc. | 5.78% | 112,434 | $1.2M | No change |
| RPRX Royalty Pharma PLC Class A | 5.74% | 21,400 | $1.2M | No change |
| CMPS Compass Pathways PLC | 5.41% | 80,000 | $1.1M | No change |
| MIST Milestone Pharmaceuticals Inc. | 5.26% | 820,000 | $1.1M | No change |
| BNTC Benitec Biopharma Inc. | 3.97% | 62,000 | $830K | No change |
| SNDX Syndax Pharmaceuticals Inc. | 3.76% | 36,000 | $787K | No change |
| BHVN Biohaven Ltd. | 3.68% | 51,700 | $769K | No change |
| GERN Geron Corp. | 3.54% | 578,000 | $740K | No change |
| QURE Uniqure NV | 3.24% | 14,700 | $677K | No change |
| ARDX Ardelyx Inc. | 3.14% | 128,650 | $656K | No change |
| LNTH Lantheus Holdings Inc. | 2.92% | 5,500 | $610K | No change |
| IRON Disc Medicine Inc. | 2.83% | 8,100 | $592K | No change |
| SRPT Sarepta Therapeutics Inc. | 2.45% | 28,500 | $512K | No change |
| HUMA Humacyte Inc. | 2.43% | 650,000 | $507K | No change |
| KURA Kura Oncology Inc. | 2.41% | 46,000 | $505K | No change |
| VTRS Viatris Inc. | 2.10% | 27,700 | $440K | No change |
| DYN Dyne Therapeutics Inc. | 1.91% | 18,000 | $400K | No change |
| BBIO Bridgebio Pharma Inc. | 1.78% | 5,000 | $372K | No change |
| EWTX Edgewise Therapeutics Inc. | 1.77% | 9,100 | $370K | No change |
| PCRX Pacira Biosciences Inc. | 1.64% | 13,500 | $342K | No change |
| RGNX Regenxbio Inc. | 1.52% | 26,600 | $319K | No change |
| RCKT Rocket Pharmaceuticals Inc. | 1.41% | 86,000 | $294K | No change |
| JANX Janux Therapeutics Inc. | 1.40% | 19,000 | $292K | No change |
| MLYS Mineralys Therapeutics Inc. | 1.36% | 10,500 | $283K | No change |
| GHRS GH Research PLC | 1.31% | 10,200 | $274K | No change |
| MCRB Seres Therapeutics Inc. | 1.19% | 31,570 | $249K | No change |
| AZTA Azenta Inc. | 1.18% | 9,700 | $248K | No change |
| JSPR Jasper Therapeutics Inc. | 0.94% | 465,000 | $196K | No change |
| INVA Innoviva Inc. | 0.89% | 8,200 | $186K | No change |
| IPHA Innate Pharma SA-Spons ADR | 0.71% | 81,151 | $149K | No change |
| ARQT Arcutis Biotherapeutics Inc. | 0.66% | 5,250 | $138K | No change |
| SPRB Spruce Biosciences Inc. | 0.26% | 1,000 | $54K | No change |
Portfolio Sells Q1 2026 → Q2 2026
| CUE Cue Biopharma Inc. | Sold out | 0.00% | −3.03 |
Portfolio Buys Q1 2026 → Q2 2026
| CUE Cue Biopharma Inc. | New | 7.99% | +7.99 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 35 | $20.9M | CUE, PRAX, MLTX, FENC, RPRX |
| Q1 2026 | 35 | $16.7M | PRAX, MLTX, RPRX, MIST, GERN |
| Q4 2025 | 39 | $19.3M | MIST, PRAX, MLTX, FENC, JSPR |
| Q3 2025 | 27 | $17.6M | MLYS, MIST, FENC, JSPR, AVDL |
| Q2 2025 | 19 | $14.7M | FENC, ARDX, KNSA, BBIO, INSM |
| Q1 2025 | 21 | $15.7M | INSM, ARDX, MLYS, FENC, KNSA |
| Q4 2024 | 19 | $19.1M | INSM, MIST, GERN, ARDX, FENC |
| Q3 2024 | 23 | $24.9M | INSM, GERN, ARDX, MIST, BHVN |
| Q2 2024 | 23 | $31.9M | ARDX, INSM, MIST, GERN, MRNS |
| Q1 2024 | 26 | $51.6M | MRNS, ARDX, MIST, KNSA, GERN |